Trimetazidine in Post-ACS Management

Guideline Position on Trimetazidine

The European Society of Cardiology explicitly does not recommend trimetazidine for ACS management, as stated in both their 2011 and 2015 guidelines 1
Trimetazidine is positioned exclusively as a second-line agent for chronic stable angina, not for acute coronary syndromes 1
The 2024 ESC Guidelines have further downgraded trimetazidine to a Class IIb recommendation (weakest positive recommendation) even for chronic coronary syndromes, and only when symptoms remain inadequately controlled despite beta-blockers and/or calcium channel blockers 1, 2

The American Heart Association recommends focus on guideline-directed medical therapy (GDMT) for post-ACS patients, including dual antiplatelet therapy (aspirin plus P2Y12 inhibitor such as ticagrelor or prasugrel) 3
The American College of Cardiology recommends high-intensity statin therapy to reduce LDL cholesterol 4
The American Heart Association recommends beta-blockers for cardioprotection and symptom control 3
The American Heart Association recommends ACE inhibitors or ARBs, particularly in patients with reduced ejection fraction or diabetes 3

Trimetazidine has a very limited role only in chronic stable angina (not ACS), only as third-line add-on therapy when angina persists despite optimal doses of beta-blockers and/or calcium channel blockers 2, 5
The European Society of Cardiology suggests trimetazidine may be reasonable in patients with low blood pressure or heart rate who cannot tolerate rate-lowering or blood pressure-lowering antianginal agents 1, 2, 5

The European Society of Cardiology states that Parkinson's disease, parkinsonism, or related movement disorders are absolute contraindications to trimetazidine 2, 5
The European Society of Cardiology states that severe renal impairment (creatinine clearance <30 mL/min) is an absolute contraindication to trimetazidine 2, 5